Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A DI PIETRO

Showing results (151-160 of 175) with videos related to

Pageof 18
Sort By:
Current Medicinal Chemistry|July 7, 2011
Targeting the multidrug ABCG2 transporter with flavonoidic inhibitors: in vitro optimization and in vivo validationA Boumendjel, S Macalou, G Valdameri, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2011
The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecanO Arnaud, A Boumendjel, A Gèze, et al.
ESMO Open|August 29, 2022
Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101Y Tomita, J Larkin, B Venugopal, et al.
Human Immunology|January 8, 2000
HLA-DRB1* and allergy to Parietaria: linkage and association analysesM D'Amato, A Picardi, T Menna, et al.
Inorganic Chemistry|October 21, 2022
Unconventional Pathways to Carbide Phase Synthesis via Thermal Decomposition of UI<sub>4</sub>(1,4-dioxane)<sub>2</sub>Maryline G Ferrier, Bradley C Childs, Chinthaka M Silva, et al.
Critical Reviews in Oncology/Hematology|December 18, 2007
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel MeetingC Gridelli, P Maione, D Amoroso, et al.
ESMO Open|April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaJ B A G Haanen, J Larkin, T K Choueiri, et al.
Journal of Neurochemistry|December 22, 2021
Colony-stimulating factor-1 receptor inhibition attenuates microgliosis and myelin loss but exacerbates neurodegeneration in the chronic cuprizone modelVictoria S B Wies Mancini, Anabella A Di Pietro, Soledad de Olmos, et al.
ESMO Open|March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patientsS Gupta, M A Climent Duran, S S Sridhar, et al.
Advances in Wound Care|February 15, 2014
Preclinical Models of Wound Healing: Is Man the Model? Proceedings of the Wound Healing Society SymposiumGayle M Gordillo, Stephanie F Bernatchez, Robert Diegelmann, et al.
Pageof 18

Showing results (151-160 of 175) with videos related to

Sort By:
Pageof 18
Current Medicinal Chemistry|July 7, 2011
Targeting the multidrug ABCG2 transporter with flavonoidic inhibitors: in vitro optimization and in vivo validationA Boumendjel, S Macalou, G Valdameri, et al.
European Journal of Cancer (Oxford, England : 1990)|January 11, 2011
The acridone derivative MBLI-87 sensitizes breast cancer resistance protein-expressing xenografts to irinotecanO Arnaud, A Boumendjel, A Gèze, et al.
ESMO Open|August 29, 2022
Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101Y Tomita, J Larkin, B Venugopal, et al.
Human Immunology|January 8, 2000
HLA-DRB1* and allergy to Parietaria: linkage and association analysesM D'Amato, A Picardi, T Menna, et al.
Inorganic Chemistry|October 21, 2022
Unconventional Pathways to Carbide Phase Synthesis via Thermal Decomposition of UI<sub>4</sub>(1,4-dioxane)<sub>2</sub>Maryline G Ferrier, Bradley C Childs, Chinthaka M Silva, et al.
Critical Reviews in Oncology/Hematology|December 18, 2007
Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an Experts Panel MeetingC Gridelli, P Maione, D Amoroso, et al.
ESMO Open|April 27, 2023
Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinomaJ B A G Haanen, J Larkin, T K Choueiri, et al.
Journal of Neurochemistry|December 22, 2021
Colony-stimulating factor-1 receptor inhibition attenuates microgliosis and myelin loss but exacerbates neurodegeneration in the chronic cuprizone modelVictoria S B Wies Mancini, Anabella A Di Pietro, Soledad de Olmos, et al.
ESMO Open|March 19, 2025
Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from the JAVELIN Bladder 100 trial in older patientsS Gupta, M A Climent Duran, S S Sridhar, et al.
Advances in Wound Care|February 15, 2014
Preclinical Models of Wound Healing: Is Man the Model? Proceedings of the Wound Healing Society SymposiumGayle M Gordillo, Stephanie F Bernatchez, Robert Diegelmann, et al.
Pageof 18